Kris Ann P. Schultz

Dr. Kris Ann P. Schultz

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KSKris Ann P. Schultz
Kris Ann P. Schultz
GWGretchen M. Williams
Gretchen M. Williams
JKJunne Kamihara
Junne Kamihara
DSDouglas R. Stewart
Douglas R. Stewart
AHAnne K. Harris
Anne K. Harris
DHD. Ashley Hill
D. Ashley Hill
Pathogenic germline DICER1 variants cause a hereditary cancer predisposition syndrome with a variety of manifestations. In addition to conferring increased cancer risks for pleuropulmonary blastoma (PPB) and ovarian sex cord–stromal tumors, particularly Sertoli–Leydig cell tumor, individuals with pathogenic germline DICER1 variants may also develop lung cysts, cystic nephroma, renal sarcoma and Wilms tumor, nodular hyperplasia of the thyroid, nasal chondromesenchymal hamartoma, ciliary body medulloepithelioma, genitourinary embryonal rhabdomyosarcoma, and brain tumors including pineoblastoma and pituitary blastoma. In May 2016, the International PPB Registry convened the inaugural International DICER1 Symposium to develop consensus testing and surveillance and treatment recommendations. Attendees from North America, Europe, and Russia provided expert representation from the disciplines of pediatric oncology, endocrinology, genetics, genetic counseling, radiology, pediatric surgery, pathology, and clinical research. Recommendations are provided for genetic testing; prenatal management; and surveillance for DICER1-associated pulmonary, renal, gynecologic, thyroid, ophthalmologic, otolaryngologic, and central nervous system tumors and gastrointestinal polyps. Risk for most DICER1-associated neoplasms is highest in early childhood and decreases in adulthood. Individual and caregiver education and judicious imaging-based surveillance are the primary recommended approaches. These testing and surveillance recommendations reflect a consensus of expert opinion and current literature. As DICER1 research expands, guidelines for screening and treatment will continue to be updated. Clin Cancer Res; 24(10); 2251–61. ©2018 AACR.

1 August 2011 in Gynecologic Oncology
Verified
Journal Article
Closed access
KSKris Ann P. Schultz
Kris Ann P. Schultz
MPM. Cristina Pacheco
M. Cristina Pacheco
JYJiandong Yang
Jiandong Yang
GWGretchen M. Williams
Gretchen M. Williams
YMYoav Messinger
Yoav Messinger
JPJohn R. Priest
John R. Priest

1 December 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
KSKris Ann P. Schultz
Kris Ann P. Schultz
AHAnne K. Harris
Anne K. Harris
MFMichael Finch
Michael Finch
LDLouis P. Dehner
Louis P. Dehner
JBJubilee B. Brown
Jubilee B. Brown
DHD. Ashley Hill
D. Ashley Hill

1 October 2016 in Journal of Oncology Practice
Verified
Journal Article
Closed access
KSKris Ann P. Schultz
Kris Ann P. Schultz
AHAnne K. Harris
Anne K. Harris
DSDominik T. Schneider
Dominik T. Schneider
RYRobert H. Young
Robert H. Young
JBJubilee Brown
Jubilee Brown
AFA. Lindsay Frazier
A. Lindsay Frazier
Ovarian sex cord-stromal tumors are clinically significant heterogeneous tumors that include several pathologic types. These tumors are often found in adolescents and young adults and can present with hormonal manifestations as well as signs and symptoms of a pelvic mass. Serum tumor markers may assist in preoperative diagnosis and surveillance. Several subtypes are associated with genetic predisposition, including those observed in patients with Peutz-Jegher syndrome. Recent studies have elucidated the relationship between Sertoli-Leydig cell tumors and DICER1 mutations. When classified as International Federation of Gynecology and Obstetrics stage Ia, most subtypes may be treated with surgery alone. Higher stage or recurrent tumors have variable prognoses that range from a usually rapid course in poorly differentiated Sertoli-Leydig cell tumor to an often prolonged course in adult granulosa cell tumors. New understanding of the molecular pathogenesis of these tumors may pave the way for novel therapeutics.

23 December 2015 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
LDLouis P. Dehner
Louis P. Dehner
YMYoav H. Messinger
Yoav H. Messinger
KSKris Ann P. Schultz
Kris Ann P. Schultz
GWGretchen M. Williams
Gretchen M. Williams
KWKathryn A. Wikenheiser-Brokamp
Kathryn A. Wikenheiser-Brokamp
DHD. Ashley Hill
D. Ashley Hill
Pleuropulmonary blastoma (PPB) is the most common primary malignant neoplasm of the lung in children. Like other solid dysontogenic neoplasms, this tumor typically presents before 7 years of age. The earliest manifestation is the presence of a lung cyst(s), which is usually recognized in the first year of life and is difficult to differentiate on the basis of imaging studies from nonneoplastic cysts of early childhood. From a multilocular cyst, PPB has the potential to progress to a high-grade multipatterned primitive sarcoma. More than 65% of all affected children have a heterozygous germline mutation in DICER1. The DICER1 PPB familial tumor predisposition syndrome is initially recognized in most cases on the basis of PPB alone but also by several other unique and characteristic extrapulmonary tumors, including pediatric cystic nephroma, nasal chondromesenchymal hamartoma, nodular lesions of the thyroid, embryonal rhabdomyosarcoma of the cervix, and ciliary body medulloepithelioma.

13 May 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KSKris Ann P. Schultz
Kris Ann P. Schultz
AHAnne Harris
Anne Harris
GWGretchen M. Williams
Gretchen M. Williams
SBShari Baldinger
Shari Baldinger
LDLeslie Doros
Leslie Doros
DHD. Ashley Hill
D. Ashley Hill